<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00138242</url>
  </required_header>
  <id_info>
    <org_study_id>VMRC-8837</org_study_id>
    <secondary_id>CDR0000439927</secondary_id>
    <secondary_id>AVENTIS-VMRC-8837</secondary_id>
    <nct_id>NCT00138242</nct_id>
  </id_info>
  <brief_title>Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer</brief_title>
  <official_title>Phase II Trial of Weekly Docetaxel (Taxotere®) and Carboplatin as Initial Chemotherapy for Women With Ovarian Cancer and Similar Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Floyd &amp; Delores Jones Cancer Institute at Virginia Mason Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving docetaxel together with carboplatin&#xD;
      works in treating patients with ovarian epithelial, fallopian tube, or peritoneal cavity&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine whether weekly administration of docetaxel and carboplatin is safer than&#xD;
           conventional three-week chemotherapy courses, in terms of reducing the rate of&#xD;
           myelosuppression, in patients with stage IC-IV ovarian epithelial, fallopian tube, or&#xD;
           peritoneal cavity cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the efficacy of this regimen, in terms of clinical response rate, time to&#xD;
           disease progression, and findings at second-look surgery, in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive docetaxel IV and carboplatin IV on days 1, 8, 15. Treatment repeats&#xD;
      every 28 days for up to 6 courses in the absence of disease progression or unacceptable&#xD;
      toxicity. Patients may then undergo optional second-look surgery. After completion of 6&#xD;
      courses of chemotherapy (and second-look surgery, if applicable), patients may receive&#xD;
      consolidation and/or salvage therapy at the discretion of the investigator.&#xD;
&#xD;
      Quality of life is assessed at baseline, before each treatment course, at the completion of&#xD;
      study treatment, and then annually for 2 years.&#xD;
&#xD;
      After completion of study treatment, patients are followed annually for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction rate of myelosuppression</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by the Functional Assessment of Cancer Therapy -Ovarian (FACT-O) questionnaire</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Findings at second look surgery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial, fallopian tube, or peritoneal cavity&#xD;
             cancer&#xD;
&#xD;
               -  Stage IC-IV disease&#xD;
&#xD;
               -  No borderline or low malignant potential tumors of any stage&#xD;
&#xD;
          -  Underwent initial surgical management, including staging, of early stage disease or&#xD;
             surgical debulking of advanced stage disease* NOTE: *Patients may delay surgical&#xD;
             debulking, if clinically indicated, until after study entry; these patients may&#xD;
             receive several courses of neoadjuvant chemotherapy prior to surgical debulking, but&#xD;
             before study entry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Alkaline phosphatase (AP) normal AND AST or ALT ≤ 5 times upper limit of normal&#xD;
                  (ULN)&#xD;
&#xD;
               -  AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN&#xD;
&#xD;
               -  AP ≤ 5 times ULN AND AST or ALT normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No prior malignancy with a poor prognosis that is at risk of relapse during study&#xD;
             participation, as determined by the principal investigator&#xD;
&#xD;
          -  No history of severe hypersensitivity reaction to drugs formulated with polysorbate 80&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy for another malignancy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard G. Muntz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Floyd &amp; Delores Jones Cancer Institute at Virginia Mason Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Floyd &amp; Delores Jones Cancer Institute at Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98111-0900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>stage I ovarian epithelial cancer</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

